Zoccali C - Search Results

1

Vasopressin beyond water: implications for renal diseases.

Bolignano D, Zoccali C. Bolignano D, et al. Among authors: zoccali c. Curr Opin Nephrol Hypertens. 2010 Sep;19(5):499-504. doi: 10.1097/MNH.0b013e32833d35cf. Curr Opin Nephrol Hypertens. 2010. PMID: 20689424 Review.

2

Neuropeptide Y, left ventricular mass and function in patients with end stage renal disease.

Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Parlongo S, Cutrupi S, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Cataliotti A, Malatino LS. Zoccali C, et al. J Hypertens. 2003 Jul;21(7):1355-62. doi: 10.1097/00004872-200307000-00025. J Hypertens. 2003. PMID: 12817184

3

Neuropeptide Y as a far-reaching neuromediator: from energy balance and cardiovascular regulation to central integration of weight and bone mass control mechanisms. Implications for human diseases.

Zoccali C. Zoccali C. Curr Opin Nephrol Hypertens. 2005 Jan;14(1):25-32. doi: 10.1097/00041552-200501000-00005. Curr Opin Nephrol Hypertens. 2005. PMID: 15586012 Review.

4

The GLU298ASP variant of nitric oxide synthase interacts with asymmetric dimethyl arginine in determining cardiovascular mortality in patients with end-stage renal disease.

Testa A, Spoto B, Tripepi G, Mallamaci F, Malatino L, Fatuzzo P, Maas R, Boeger R, Zoccali C. Testa A, et al. Among authors: zoccali c. J Hypertens. 2005 Oct;23(10):1825-30. doi: 10.1097/01.hjh.0000182528.59687.d1. J Hypertens. 2005. PMID: 16148605

5

Biomarkers in chronic kidney disease: utility and issues towards better understanding.

Zoccali C. Zoccali C. Curr Opin Nephrol Hypertens. 2005 Nov;14(6):532-7. doi: 10.1097/01.mnh.0000185982.10201.a7. Curr Opin Nephrol Hypertens. 2005. PMID: 16205471 Review.

6

Urotensin II in end-stage renal disease: an inverse correlate of sympathetic function and cardiac natriuretic peptides.

Mallamaci F, Cutrupi S, Pizzini P, Tripepi G, Zoccali C. Mallamaci F, et al. Among authors: zoccali c. J Nephrol. 2005 Nov-Dec;18(6):727-32. J Nephrol. 2005. PMID: 16358231

7

Renal impairment: a risk factor for ischemic heart disease.

Zoccali C. Zoccali C. Curr Opin Pharmacol. 2006 Apr;6(2):221-5. doi: 10.1016/j.coph.2005.11.007. Epub 2006 Feb 17. Curr Opin Pharmacol. 2006. PMID: 16483843 Review.

8

Asymmetric dimethylarginine (ADMA): a cardiovascular and renal risk factor on the move.

Zoccali C. Zoccali C. J Hypertens. 2006 Apr;24(4):611-9. doi: 10.1097/01.hjh.0000217839.26971.8d. J Hypertens. 2006. PMID: 16531785 Review.

9

Asymmetric dimethylarginine: a new player in the pathogenesis of renal disease?

Zoccali C, Kielstein JT. Zoccali C, et al. Curr Opin Nephrol Hypertens. 2006 May;15(3):314-20. doi: 10.1097/01.mnh.0000222701.22583.e8. Curr Opin Nephrol Hypertens. 2006. PMID: 16609301 Review.

10

Urotensin II and biomarkers of endothelial activation and atherosclerosis in end-stage renal disease.

Mallamaci F, Cutrupi S, Pizzini P, Tripepi G, Zoccali C. Mallamaci F, et al. Among authors: zoccali c. Am J Hypertens. 2006 May;19(5):505-10. doi: 10.1016/j.amjhyper.2005.10.019. Am J Hypertens. 2006. PMID: 16647624

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,046 results

Search Page

Filters